[
  {
    "ts": null,
    "headline": "PFE New & Acquired Drugs Back 1H Top-Line Growth: Will the Trend Last?",
    "summary": "Pfizer's new and acquired drugs record sales of $4.7B in H1 as COVID-products related volatility eases.",
    "url": "https://finnhub.io/api/news?id=b59a7382ab24ae320a1dd9379168cb43dbb8939d95b9279b31facd1b3f8ca225",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755104100,
      "headline": "PFE New & Acquired Drugs Back 1H Top-Line Growth: Will the Trend Last?",
      "id": 136339640,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Pfizer's new and acquired drugs record sales of $4.7B in H1 as COVID-products related volatility eases.",
      "url": "https://finnhub.io/api/news?id=b59a7382ab24ae320a1dd9379168cb43dbb8939d95b9279b31facd1b3f8ca225"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
    "summary": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=9ac3c1fbf134022aff6077ed49cc507eecf1fc16a1ef17c70fcbb0b611788df5",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755103200,
      "headline": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
      "id": 136355806,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=9ac3c1fbf134022aff6077ed49cc507eecf1fc16a1ef17c70fcbb0b611788df5"
    }
  },
  {
    "ts": null,
    "headline": "Will Zanzalintinib Ease Out EXEL's Reliance on Cabometyx for Growth?",
    "summary": "Exelixis reports strong phase III results for zanzalintinib in metastatic colorectal cancer, raising hopes beyond Cabometyx.",
    "url": "https://finnhub.io/api/news?id=39c0d26d75f4c4c0cfdc73fdb5edb4a2c3b5734d2b172198bc861833bff60f4f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755089520,
      "headline": "Will Zanzalintinib Ease Out EXEL's Reliance on Cabometyx for Growth?",
      "id": 136339641,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Exelixis reports strong phase III results for zanzalintinib in metastatic colorectal cancer, raising hopes beyond Cabometyx.",
      "url": "https://finnhub.io/api/news?id=39c0d26d75f4c4c0cfdc73fdb5edb4a2c3b5734d2b172198bc861833bff60f4f"
    }
  },
  {
    "ts": null,
    "headline": "Will Breyanzi's Strong Uptake Help BMY Offset Generic Competition?",
    "summary": "Bristol Myers' Breyanzi sales surged 125% in Q2 to $344M, fueled by new approvals, strong demand and expanded market reach.",
    "url": "https://finnhub.io/api/news?id=7f68533e091d6ef6ec4b6e0647668645309d935bb43db2e413565ee8a28d293c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755088560,
      "headline": "Will Breyanzi's Strong Uptake Help BMY Offset Generic Competition?",
      "id": 136339844,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol Myers' Breyanzi sales surged 125% in Q2 to $344M, fueled by new approvals, strong demand and expanded market reach.",
      "url": "https://finnhub.io/api/news?id=7f68533e091d6ef6ec4b6e0647668645309d935bb43db2e413565ee8a28d293c"
    }
  },
  {
    "ts": null,
    "headline": "Want Over $2,100 in Annual Dividends? Invest $12,000 Into Each of These 3 High-Yielding Stocks",
    "summary": "The dividend stocks listed below all yield more than 5% and look like safe long-term buys.",
    "url": "https://finnhub.io/api/news?id=202b34ac448fc69b9e25bd0b806fe49692633b614d68ebd2317187c5ba0022d2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755080760,
      "headline": "Want Over $2,100 in Annual Dividends? Invest $12,000 Into Each of These 3 High-Yielding Stocks",
      "id": 136328359,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "The dividend stocks listed below all yield more than 5% and look like safe long-term buys.",
      "url": "https://finnhub.io/api/news?id=202b34ac448fc69b9e25bd0b806fe49692633b614d68ebd2317187c5ba0022d2"
    }
  },
  {
    "ts": null,
    "headline": "Evotec SE Reports H1 2025 Results: Strong Progress on Strategy Execution",
    "summary": "Strategy for sustainable profitable growth progressing as planned with improving revenue mix and ahead-of-plan cost reductions Reporting segment formerly known as Shared R&D renamed to Discovery & Preclinical Development (\"D&PD\") to better reflect ...",
    "url": "https://finnhub.io/api/news?id=47198c117c4cc590eb09ba5c9eba6233dd21a0ea06d5115d1b409322d955710a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755062700,
      "headline": "Evotec SE Reports H1 2025 Results: Strong Progress on Strategy Execution",
      "id": 136328470,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Strategy for sustainable profitable growth progressing as planned with improving revenue mix and ahead-of-plan cost reductions Reporting segment formerly known as Shared R&D renamed to Discovery & Preclinical Development (\"D&PD\") to better reflect ...",
      "url": "https://finnhub.io/api/news?id=47198c117c4cc590eb09ba5c9eba6233dd21a0ea06d5115d1b409322d955710a"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb’s Q2 Earnings Call: Our Top 5 Analyst Questions",
    "summary": "Bristol-Myers Squibb’s second quarter saw flat overall sales, but the company surpassed Wall Street expectations for both revenue and non-GAAP profit, with operating margin improving year on year. Despite these beats, the market responded negatively, reflecting concerns raised by management about continued macro and competitive pressures. CEO Chris Boerner pointed to strong demand across the company’s growth portfolio, especially in oncology and hematology, while also acknowledging regulatory wi",
    "url": "https://finnhub.io/api/news?id=bb9b3737f2efbce81d1cb1047e61b667244e2df3b2b002b3a60852292f99a114",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755059159,
      "headline": "Bristol-Myers Squibb’s Q2 Earnings Call: Our Top 5 Analyst Questions",
      "id": 136328471,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol-Myers Squibb’s second quarter saw flat overall sales, but the company surpassed Wall Street expectations for both revenue and non-GAAP profit, with operating margin improving year on year. Despite these beats, the market responded negatively, reflecting concerns raised by management about continued macro and competitive pressures. CEO Chris Boerner pointed to strong demand across the company’s growth portfolio, especially in oncology and hematology, while also acknowledging regulatory wi",
      "url": "https://finnhub.io/api/news?id=bb9b3737f2efbce81d1cb1047e61b667244e2df3b2b002b3a60852292f99a114"
    }
  },
  {
    "ts": null,
    "headline": "BMY Q2 Deep Dive: Pipeline Progress, Guidance Revision, and Strategic Partnerships Shape Outlook",
    "summary": "Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced better-than-expected revenue in Q2 CY2025, but sales were flat year on year at $12.27 billion. The company’s full-year revenue guidance of $47 billion at the midpoint came in 1.6% above analysts’ estimates. Its non-GAAP profit of $1.46 per share was 32.6% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=b0b1b9f69a1806ff2bd9d4236472604075cfb93e6c8dfb9204cf3a93e132296b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755057644,
      "headline": "BMY Q2 Deep Dive: Pipeline Progress, Guidance Revision, and Strategic Partnerships Shape Outlook",
      "id": 136328472,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced better-than-expected revenue in Q2 CY2025, but sales were flat year on year at $12.27 billion. The company’s full-year revenue guidance of $47 billion at the midpoint came in 1.6% above analysts’ estimates. Its non-GAAP profit of $1.46 per share was 32.6% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=b0b1b9f69a1806ff2bd9d4236472604075cfb93e6c8dfb9204cf3a93e132296b"
    }
  }
]